Health & Biotech
The world’s biggest marijuana stock soars to an all-time high
Institutional investor circles colon cancer hopeful Rhythm Biosciences
Vet Greencross reports lower profit but investors like the outlook
Directors of cannabis play Creso Pharma buy in to capital raising
Is Anatara good value after 40pc share price drop?
Drug developer Pharmaxis turns loss into $6m profit
Tax cut takes a bite out of Penthrox maker Medical Development’s profits
Corona maker sinks $4bn into Aussie pot stock AusCann’s biggest shareholder
Wattle gets baby food into China but is still waiting for formula nod; shares up 15pc
US fighter pilots will cough into an Aussie smartphone app to see if they’re fit to fly
Three key things investors should look for when investing in biotechs
Salmon farmer Huon dives 16pc after warm summer reduces fish haul
Actinogen hits enrolment milestone for Alzheimer’s clinical trial
Here’s how every ASX health stock has performed over the past year
These six Aussie pot stocks raised 70pc of cannabis capital in 2018
Allegra swings to loss as it works on implanting kangaroo tendons in humans
Asian private equity funds back $20-per-share bid for Capilano Honey
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
